By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Calithera Biosciences, Inc. 

7000 Shoreline Court
Suite 255
South San Francisco  California  94080  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Calithera Biosciences (CALA) Reports Second Quarter 2017 Financial Results And Recent Highlights 8/9/2017 1:29:34 PM
Calithera Biosciences (CALA) Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma 8/7/2017 11:37:58 AM
Calithera Biosciences (CALA) To Report Second Quarter 2017 Financial Results On Tuesday, August 8, 2017 8/2/2017 1:23:02 PM
Calithera Biosciences (CALA) Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma 6/7/2017 6:14:06 AM
Calithera Biosciences (CALA) Release: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented At The ASCO Annual Meeting 6/5/2017 1:24:47 PM
Calithera Biosciences (CALA) Reports First Quarter 2017 Financial Results And Recent Highlights 5/10/2017 12:16:50 PM
Bristol-Myers Squibb (BMY) And Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo (Nivolumab) In Combination With CB-839 Into Non-Small Cell Lung Cancer And Melanoma 5/10/2017 10:25:31 AM
Calithera Biosciences (CALA) To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017 5/3/2017 10:00:58 AM
Incyte (INCY) And Calithera Biosciences (CALA) Announce Global Collaboration To Develop And Commercialize CB-1158, A First-In-Class, Small Molecule Arginase Inhibitor 1/30/2017 9:40:38 AM
Bay Area's Calithera Biosciences (CALA) Rockets After Getting $53 Million Upfront in Cancer Deal With Incyte (INCY) 1/30/2017 5:30:29 AM
1234567
//-->